MultiBank Group Completed First $MBG Buyback & Burn, Removing 4.86M Tokens After Record H1 2025 Financial Results.
27.8.2025 12:40:00 CEST | Business Wire | Press Release
MultiBank Group, the world’s largest financial derivatives institution, has announced the successful execution of its buyback and burn program, permanently removing 4,860,000 $MBG tokens from circulation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250827632341/en/
MultiBank Group Completed First $MBG Buyback & Burn, Removing 4.86M Tokens After Record H1 2025 Financial Results.
The milestone follows the Group’s record-breaking financial results, with H1 2025 revenue reaching $209 million and an average daily trading turnover of $36 billion since the Token Generation Event on July 22.
The $MBGBuyback and Burn program underscores MultiBank Group’s commitment to rewarding its community while strengthening the long-term fundamentals of the $MBG Utility Token. By reducing supply, the Group is actively driving scarcity and reinforcing token value. The initiative is structured to scale significantly, with up to $58.2 million worth of $MBG expected to be retired in the first year and a cumulative $440 million over five years.
The move builds on the token’s strong early performance. Since listing on July 22 across MultiBank.io, MEXC, Gate.io, Uniswap, and BingX, $MBG has climbed to seven times its debut price, attracting worldwide attention as one of the market’s most closely followed new assets.
Naser Taher, Founder and Chairman of MultiBank Group, said:
“This first buyback proves the power of our ecosystem, bridging TradFi, our institutional ECN, a regulated crypto exchange, and real-world asset (RWA) tokenization. $MBG is becoming the utility token at the core of it all. Today’s burn is just the start — with additional utilities, greater scarcity, and more community rewards coming soon.”
The $MBG Utility Token powers MultiBank’s four-pillar ecosystem:
- MultiBank TradFi: The Group’s CFD powerhouse, which generated $362 million in revenue last year and reported record-breaking H1 2025 results of $209 million. $MBG can be used for reduced fees and enhanced platform features.
- MEX Exchange (Institutional ECN): A $23.7 billion hybrid FX and crypto ECN for emerging markets, with $MBG streamlining settlement, mitigating counterparty risk, and enabling smart contract-based margining.
- MultiBank.io (crypto exchange): Regulated across multiple jurisdictions, including the UAE and Australia, it offers spot and leveraged trading. $MBG provides reduced costs and benefits, including launchpad participation, staking, and token-driven opportunities.
- MultiBank.io RWA: Built on Mavryk’s layer-1 blockchain, this division underpins the world’s largest RWA tokenization project to date, a $3 billion real estate deal with MAG Lifestyle Development, where $MBG holders receive fee discounts and early access.
With more than two million clients, 17+ financial licenses across five continents, and an unblemished compliance record since 2005, MultiBank Group is accelerating its blockchain and DeFi infrastructure to introduce a series of new initiatives in the months ahead.
ABOUT MULTIBANK GROUP
MultiBank Group, established in California, USA in 2005, is a global leader in financial derivatives. With over 2 million clients in 100+ countries and a daily trading volume exceeding $35 billion, it offers a broad range of brokerage and asset management services. Renowned for innovative trading solutions, robust regulatory compliance, and exceptional customer service, the Group is regulated by 17+ top-tier financial authorities across five continents. Its award-winning platforms provide up to 500:1 leverage across Forex, Metals, Shares, Commodities, Indices, and Cryptocurrencies. MultiBank Group has received over 80 international awards for trading excellence and regulatory compliance.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250827632341/en/
Contacts
mohammad.shakfeh@multibankfx.com
00971585754191
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom